azomycin has been researched along with rifamycins in 12 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (8.33) | 18.7374 |
1990's | 1 (8.33) | 18.2507 |
2000's | 3 (25.00) | 29.6817 |
2010's | 5 (41.67) | 24.3611 |
2020's | 2 (16.67) | 2.80 |
Authors | Studies |
---|---|
Hamilton-Miller, JM | 1 |
Walker, CB | 1 |
He, G; Xiao, H | 1 |
Doi, N | 1 |
Yeager, H | 1 |
Lienhardt, C; Raviglione, MC; Vernon, A | 1 |
Nuermberger, EL; Spigelman, MK; Yew, WW | 1 |
Cambau, E; Guillard, T | 1 |
Alsultan, A; Belchis, DA; Dutta, NK; Gniadek, TJ; Karakousis, PC; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Pinn, ML | 1 |
Nath, M; Tandon, R | 1 |
Chen, J; Ding, C; Doyle, T; Duncan, L; Ebright, RH; He, S; Lin, W; Liu, Y; Lynch, AS; Ma, Z; Molodtsov, V; Nguyen, P; Pulse, M; Robertson, GT; Wang, H; Weiss, WJ; Xu, X; Yuan, Y; Zhuang, Z | 1 |
Nahid, P; Velásquez, GE | 1 |
9 review(s) available for azomycin and rifamycins
Article | Year |
---|---|
Antimicrobial agents acting against anaerobes.
Topics: Aminoglycosides; Anaerobiosis; Animals; Anti-Bacterial Agents; Bacteria; Chloramphenicol; Clindamycin; Colistin; Disease Models, Animal; Erythromycin; Fusidic Acid; Humans; Lactams; Lincomycin; Microbial Sensitivity Tests; Nitrofurans; Nitroimidazoles; Polymyxins; Rifamycins; Sulfamethoxazole; Tetracyclines; Trimethoprim; Vancomycin | 1975 |
Selected antimicrobial agents: mechanisms of action, side effects and drug interactions.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Cell Membrane Permeability; Cell Wall Skeleton; Cephalosporins; Clindamycin; Drug Interactions; Humans; Macrolides; Nitroimidazoles; Nucleic Acid Synthesis Inhibitors; Penicillins; Quinolones; Rifamycins; Tetracyclines | 1996 |
[Recent advance of anti-tuberculous agents].
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Enviomycin; Fluoroquinolones; Lactams; Macrolides; Nitroimidazoles; Phenazines; Phenothiazines; Rifamycins; Thioacetazone | 2000 |
[Anti-tuberculosis drugs].
Topics: 4-Quinolones; Anti-Infective Agents; Antitubercular Agents; Chlorpromazine; Drug Delivery Systems; Drug Design; Drug Resistance, Multiple, Bacterial; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Rifamycins | 2003 |
New drugs and vaccines.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Fluoroquinolones; Humans; Mycobacterium bovis; Mycobacterium tuberculosis; Nitroimidazoles; Quinolones; Rifamycins; Tuberculosis; Tuberculosis Vaccines; World Health Organization | 2007 |
New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Drug Industry; Drug Therapy, Combination; Female; Fluoroquinolones; Forecasting; Humans; Male; Nitroimidazoles; Rifamycins; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2010 |
Current development and future prospects in chemotherapy of tuberculosis.
Topics: Adamantane; Animals; Antitubercular Agents; Carbapenems; Clinical Trials as Topic; Diarylquinolines; Drug Delivery Systems; Ethylenediamines; Fluoroquinolones; Humans; Isonicotinic Acids; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Patient Compliance; Pyrroles; Quinolines; Rifamycins; Tuberculosis, Pulmonary | 2010 |
Antimicrobials that affect the synthesis and conformation of nucleic acids.
Topics: Anti-Infective Agents; Coumarins; DNA Replication; DNA, Bacterial; Nitrofurans; Nitroimidazoles; Nucleic Acid Conformation; Nucleic Acids; Pyrimidines; Quinolones; Rifamycins; Sulfanilamides; Transcription, Genetic | 2012 |
Tackling Drug-Resistant Tuberculosis: Current Trends and Approaches.
Topics: Antitubercular Agents; Benzothiazoles; Cell Wall; Clinical Trials as Topic; Ethylenediamines; Mycobacterium tuberculosis; Nitroimidazoles; Quinolones; Rifamycins; Tuberculosis, Multidrug-Resistant | 2017 |
3 other study(ies) available for azomycin and rifamycins
Article | Year |
---|---|
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen.
Topics: Animals; Antitubercular Agents; Area Under Curve; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Guinea Pigs; Lung; Mycobacterium tuberculosis; Nitroimidazoles; Organ Size; Pyrazinamide; Recurrence; Rifamycins; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2013 |
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens.
Topics: Anaerobiosis; DNA-Directed RNA Polymerases; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Rifamycins | 2022 |
Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-susceptible Tuberculosis.
Topics: Antitubercular Agents; Humans; Nitroimidazoles; Rifamycins; Tuberculosis | 2023 |